CARMIDO: Molecule repurposing in the treatment of obstructive cardiopathies

APPLICATIONS

• Treatment of severe, uncomfortable and incapacitating symptoms associated with obstructive cardiopathies
• Global improvement of the quality of life of the patient
• Human or veterinary purposes

The problem : Drug treatments such as beta-blockers or calcium channel blockers are moderately effective and sometimes associated with unacceptable side effects in hypertrophic cardiomyopathy patient

DESCRIPTION

• Repurposing molecule improving symptoms associated with obstructive cardiopathies and especially hypertrophic cardiomyopathy:
  • exercise breathlessness
  • exercise chest pain
  • exercise discomfort
  • exercise dizziness
• Validation with a first serie of human obstructive heart diseases
• Reduction of symptoms at rest or during effort
• Immediate decrease of intraventricular obstruction and hyperkinetic state
• Ongoing phase II clinical study on 40 patients

BENEFITS

• Efficient treatment for reducing severe symptoms of patients suffering from obstructive cardiopathies
• Large improvement in patients’ daily life
• Safer approach compared to severe medications or invasive therapies currently used.

IP

Patent application: WO 2017/021283 A1